Alzheimer’s Disease/Dementia News

In a phase 3 trial of pimavanserin that came to a premature halt for efficacy, patients with dementia-related psychosis who continued the treatment had a lower risk for relapse than those who were switched to placebo, researchers reported.

A cerebrospinal fluid alpha-synuclein real-time, quaking-induced conversion assay demonstrated efficacy as a “robust biomarker” for identifying mild cognitive impairment due to probable Lewy body disease, according to researchers.

Individuals with a “cognitively active lifestyle” delayed dementia onset up to 5 years compared with individuals who engaged in low levels of cognitive activity, according to findings from a longitudinal cohort study published in Neurology.

An intervention researchers hoped would improve infection management did not significantly reduce antimicrobial use among nursing home residents with dementia, data showed.

An updated position statement issued by the American Academy of Neurology about ethical considerations that often arise in the treatment of patients with dementia revises the organization’s statement from 1996 on the same topic.

Long-term results from the ASCOT trial demonstrated that an amlodipine-based BP-lowering regimen reduced stroke risk compared with an atenolol-based regimen, although no benefit in dementia risk was observed.

The FDA approved an updated label for Aduhelm that emphasizes the disease stages examined in the clinical trials, specifically stating that the agent should be initiated in patients with mild cognitive impairment or dementia.

Longer exposure to endogenous estrogen is associated with increased levels of Alzheimer’s disease biomarkers in women, according to a study published in Menopause.

The APOE e4 allele correlated with earlier clinical and biomarker-related changes of Alzheimer’s disease among patients with Down syndrome, according to results from a dual-center cohort study published in JAMA Neurology.

Tau PET imaging successfully predicted longitudinal changes in cognition among individuals with varying degrees of cognitive function, according to results from a prognostic study published in JAMA Neurology.